From: Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
Characteristics | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 |
---|---|---|---|---|---|---|---|
Age at diagnosis | 40–50 | 50–60 | 30–40 | 70–80 | 70–80 | 70–80 | 50–60 |
Body mass index | 20.7 | 27.0 | 22.8 | 27.0 | 31.4 | 29.0 | 25.0 |
Family history | No | No | Yes | No | Yes | No | No |
Smoke | No | No | No | Yes | No | No | No |
Alcohol intake | No | Yes | No | No | Yes | No | No |
Obesity | No | No | No | No | Yes | No | No |
Side | Left | Left | Right | Left | Left | Right | Left |
Stage | IV | II | II | III | I | III | Unknown |
Histotype | Ductal | Ductal | Ductal | Ductal | Ductal | Ductal | Ductal |
HR status | ER+ | ER-/PgR- | ER+/PgR+ | ER+/PgR+ | ER+/PgR+ | ER+/PgR+ | Unknown |
HER-2 positive | Yes | Unknown | No | Yes | No | No | Unknown |
Ki-67 high-level (cutoff 20 %) | Unknown | Unknown | No | Yes | Yes | Yes | Unknown |
Surgery | M | M | M | Q | M | M | M |
Radiotherapy | Yes | No | No | Yes | No | No | No |
Chemotherapy | Yes | Yes | Yes | Unknown | No | Yes | No |
Endocrine therapy | Yes | No | Yes | Unknown | Unknown | Yes | No |
Trastuzumab | Yes | No | No | Unknown | No | No | No |
Relapse | Yes | No | Yes | Yes | No | Unknown | Yes |
Other tumors | Yes | No | Yes | Yes | No | No | Yes |
BRCA mutation | No test | No test | BRCA 1 | BRCA 2 | BRCA 2 | No test | No test |
Follow-up (days) | 2465 | 5706 | 1795 | 1096 | 1031 | 173 | 3713 |